Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Positive Two-Year Data Boost Prospects For Vivus' Qnexa

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm reports continued weight loss advantage as well as improvement in weight-related co-morbidities, which has been a request from FDA's advisory committee.

You may also be interested in...

Arena Must Deal With Rat Neoplasms To Move Forward With Lorqess

A major task confronting Arena as it pursues approval of Lorqess is to provide FDA with an explanation that shows the neoplasms found in rats during animal studies of the obesity drug are not a predictor of cancer risk in humans.

FDA Pressed At Meridia Committee Review To Finalize Obesity Drug Guidance

FDA is facing strong pressure from its own advisory committee members to finalize development standards for weight-loss drugs.

Qnexa May Get Staged Launch After No Vote From Advisory Committee

Safety concerns and a large market potential for Vivus's obesity drug combine to produce an advisory panel recommendation that leaves FDA "a little surprised."


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts